Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation

Peter Gal, Gyorgyi Feldmajer, Margarida Augusto (), Ray Gani, Emma Hook, Ash Bullement, Zoe Philips and Inger Smith
Additional contact information
Peter Gal: Evidera
Gyorgyi Feldmajer: Evidera
Margarida Augusto: Novo Nordisk A/S
Ray Gani: Evidera
Emma Hook: Delta Hat
Ash Bullement: Delta Hat
Zoe Philips: Delta Hat
Inger Smith: White Box Health Economics Ltd

PharmacoEconomics, 2025, vol. 43, issue 5, No 10, 595-596

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-025-01475-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:43:y:2025:i:5:d:10.1007_s40273-025-01475-2

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-025-01475-2

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().